Skip to content

Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study

Research Square September 7, 2026 preprint DOI: 10.21203/rs.3.rs-10923483/v1 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Longitudinal biomarker study
Population Patients with treatment-resistant depression
Intervention Intranasal esketamine
Topics Depression Esketamine
Key findings Higher metabolic burden was associated with poorer response to repeated intranasal esketamine, indicating that metabolic factors may influence treatment outcomes in treatment-resistant depression.

Abstract

Metabolic Burden and Response to Repeated Intranasal Esketamine in Treatment-Resistant Depression: A Longitudinal Multidomain Biomarker Study